Articles

GLP-1 and muscle

What the evidence says about lean mass while using GLP-1 receptor agonists, and what it does not.

Article list

GLP-1 and muscle

What controlled trials actually measured about lean mass on GLP-1s

The large trials reported total body weight. Body composition came from small imaging substudies — and those instruments have limits of their own.Reviewed 6 minSecondary sources · 7 sourcesSemaglutideTirzepatideLiraglutideGLP-1 and muscle

Resistance training and protein during a deficit: what the trials measured

The training and protein literature is large and reasonably consistent. It was also built almost entirely in people who were not taking a GLP-1 receptor agonist.Reviewed 5 minPrimary trials · 7 sourcesSemaglutideTirzepatideGLP-1 and muscle

What the trial record reports on discontinuation

One trial reports 16.6% stopping because of adverse events. Another reports 2.4%. Both are correct, and they are not measuring the same thing.Reviewed 9 minPrimary trials · 10 sourcesSemaglutideTirzepatideLiraglutideGLP-1 and muscle

Gastrointestinal effects: what the trials actually measured

This is the part of the record that has denominators. Percentages against a placebo column, from named trials, with the number of participants printed beside them.Reviewed 9 minPrimary trials · 10 sourcesSemaglutideTirzepatideLiraglutideGLP-1 and muscle

Body composition by sex on GLP-1s: what the substudies did not report

Everyone wants to know whether men and women lose lean mass differently on these drugs. The registry record shows why nobody can answer from these trials.Reviewed 6 minPrimary trials · 6 sourcesSemaglutideTirzepatide